There is a lot of talk these days about whether the market is in a bubble and that a crash akin to 1987 may be lurking around the corner, ready to take a huge bite out of your portfolio.
Nowhere in the market is this talk more pervasive than in the biotech sector, where multibagger returns have become commonplace, even outside the speculative penny-stock realm. In the past year alone, of a possible 165 biotech stocks with a market cap of at least $200 million, 37(!) of them have at least doubled in share price.
Seeing that kind of easy money has led to a surge of biotech initial public offerings. There were nearly 40 last year, and we are on pace to shatter that figure this year. However, there is a newer IPO craze developing at the intersection of technology and medicine.
On this edition of Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss the IMS Health (NYSE:IMS) public offering, how it compares with another recent high-profile IPO from Castlight (NYSE:CSLT), and where they see this marriage of health care and big data heading in the coming years.